New Age Alpha Advisors LLC Takes $8.55 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

New Age Alpha Advisors LLC bought a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 70,340 shares of the biotechnology company’s stock, valued at approximately $8,553,000. New Age Alpha Advisors LLC owned approximately 0.07% of Sarepta Therapeutics at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SRPT. Norges Bank purchased a new position in shares of Sarepta Therapeutics during the 4th quarter valued at $126,315,000. NEOS Investment Management LLC lifted its position in shares of Sarepta Therapeutics by 13.9% in the fourth quarter. NEOS Investment Management LLC now owns 1,943 shares of the biotechnology company’s stock valued at $236,000 after acquiring an additional 237 shares in the last quarter. Sava Infond d.o.o. bought a new position in shares of Sarepta Therapeutics in the fourth quarter worth about $365,000. WINTON GROUP Ltd bought a new position in shares of Sarepta Therapeutics in the fourth quarter worth about $678,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Sarepta Therapeutics by 11.1% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,429 shares of the biotechnology company’s stock worth $307,000 after purchasing an additional 243 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Stock Down 1.5 %

Shares of SRPT opened at $71.81 on Friday. The firm has a market capitalization of $6.97 billion, a P/E ratio of 57.45 and a beta of 0.79. Sarepta Therapeutics, Inc. has a 12-month low of $70.91 and a 12-month high of $173.25. The firm has a fifty day moving average price of $103.61 and a 200-day moving average price of $116.46. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on SRPT shares. Needham & Company LLC reaffirmed a “buy” rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $163.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Scotiabank reduced their target price on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating on the stock in a report on Thursday, March 20th. Deutsche Bank Aktiengesellschaft decreased their target price on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a research report on Wednesday, March 19th. Finally, HC Wainwright reissued a “sell” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday, March 19th. One analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $167.41.

Insiders Place Their Bets

In related news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.